TY - JOUR
T1 - High-Grade Osteosarcoma of the Foot
T2 - Presentation, Treatment, Prognostic Factors, and Outcome of 23 Cooperative Osteosarcoma Study Group COSS Patients
AU - Schuster, Anne J.
AU - Kager, Leo
AU - Reichardt, Peter
AU - Baumhoer, Daniel
AU - Csóka, Monika
AU - Hecker-Nolting, Stefanie
AU - Lang, Susanna
AU - Lorenzen, Sylvie
AU - Mayer-Steinacker, Regine
AU - Von Kalle, Thekla
AU - Kevric, Matthias
AU - Werner, Mathias
AU - Windhager, Reinhard
AU - Wirth, Thomas
AU - Bielack, Stefan S.
N1 - Publisher Copyright:
© 2018 Anne J. Schuster et al.
PY - 2018
Y1 - 2018
N2 - Osteosarcoma of the foot is a very rare presentation of a rare tumor entity. In a retrospective analysis, we investigated tumor- and treatment-related variables and outcome of patients registered in the Cooperative Osteosarcoma Study Group (COSS) database between January 1980 and April 2016 who suffered from primary high-grade osteosarcoma of the foot. Among the 23 eligible patients, median age was 32 years (range: 6-58 years), 10 were female, and 13 were male. The tarsus was the most commonly affected site (n=16). Three patients had primary metastases. All patients were operated: 5 underwent primary surgery and 18 received surgery following preoperative chemotherapy. In 21 of the 23 patients, complete surgical remission was achieved. In 4 of 17 patients, a poor response to neoadjuvant chemotherapy was observed in the resected primary tumors. Median follow-up was 4.2 years (range: 0.4-18.5). At the last follow-up, 15 of the 23 patients were alive and 8 had died. Five-year overall and event-free survival estimates were 64% (standard error (SE) 12%) and 54% (SE 13%), which is similar to that observed for osteosarcoma in general. Event-free and overall survival correlated with primary metastatic status and completeness of surgery. Our findings show that high-grade osteosarcoma in the foot has a similar outcome as osteosarcoma of other sites.
AB - Osteosarcoma of the foot is a very rare presentation of a rare tumor entity. In a retrospective analysis, we investigated tumor- and treatment-related variables and outcome of patients registered in the Cooperative Osteosarcoma Study Group (COSS) database between January 1980 and April 2016 who suffered from primary high-grade osteosarcoma of the foot. Among the 23 eligible patients, median age was 32 years (range: 6-58 years), 10 were female, and 13 were male. The tarsus was the most commonly affected site (n=16). Three patients had primary metastases. All patients were operated: 5 underwent primary surgery and 18 received surgery following preoperative chemotherapy. In 21 of the 23 patients, complete surgical remission was achieved. In 4 of 17 patients, a poor response to neoadjuvant chemotherapy was observed in the resected primary tumors. Median follow-up was 4.2 years (range: 0.4-18.5). At the last follow-up, 15 of the 23 patients were alive and 8 had died. Five-year overall and event-free survival estimates were 64% (standard error (SE) 12%) and 54% (SE 13%), which is similar to that observed for osteosarcoma in general. Event-free and overall survival correlated with primary metastatic status and completeness of surgery. Our findings show that high-grade osteosarcoma in the foot has a similar outcome as osteosarcoma of other sites.
UR - http://www.scopus.com/inward/record.url?scp=85048157194&partnerID=8YFLogxK
U2 - 10.1155/2018/1632978
DO - 10.1155/2018/1632978
M3 - Article
AN - SCOPUS:85048157194
SN - 1357-714X
VL - 2018
JO - Sarcoma
JF - Sarcoma
M1 - 1632978
ER -